What Are Chinese Pharma CEOs Ranting About? (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
Top pharma executives in China get a chance to air their rants during a once-a-year “meet the regulators” session in Beijing, while regulators including the CFDA deputy commissioner share candid views on pertinent industry issues such as the drug approval backlog, pricing, provincial tenders and the essential drug list.
You may also be interested in...
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.